ABC | Volume 110, Nº1, January 2018

Original Article Stephan et al Mobile health and atrial fibrillation Arq Bras Cardiol. 2018; 110(1):7-15 1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014;129(8):837-47. doi: 10.1161/ CIRCULATIONAHA.113.005119. 2. Perera KS, Vanassche T, Bosch J, Swaminathan B, Mundl H, Giruparajah M, et al; ESUS Global Registry Investigators. Global survey of the frequency of atrial fibrillation-associated stroke: embolic stroke of undetermined source global registry.Stroke.2016;47(9):2197-202.doi:10.1161/STROKEAHA.116.013378. 3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. PMID: 17577005. 4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi: 10.1056/ NEJMoa1009638. 5. Conolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi: 10.1056/NEJMoa0905561. 6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039. 7. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-267. doi: 10.1161/ CIR.0000000000000041. Erratum in: Circulation. 2014;130(23):e272-4. 8. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaborationwithEACTS.EurHear J.2016;37(38):2893-962.doi:10.1093/ eurheartj/ehw210. 9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-72. doi: 10.1378/chest.09-1584. 10. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/ Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-80. doi: 10.1016/j.jacc.2010.09.024. 11. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT2R2score.Chest.2013;144(5):1555-63.doi:10.1378/chest.13-0054. 12. Dzeshka MS, Lane DA, Lip GY. Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2DS2- VASc, R2CHADS2, HAS-BLED, ATRIA, and more). Clin Cardiol. 2014;37(10):634-44. doi: 10.1002/clc.22294. 13. Beyer-Westendorf J,EhlkenB,EversT.Real-worldpersistenceandadherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150-7. doi: 10.1093/europace/euv421. 14. Almeida ED, Guimaraes RB, Stephan LS, Medeiros AK, Foltz K, Santanna RT, et al. Clinical differences between subtypes of atrial fibrillation and flutter: cross-sectional registry of 407 patients. Arq Bras Cardiol. 2015;105(1):1-10. doi: http://dx.doi.org/10.5935/abc.20150049 15. Leiria TL, Pellanda L, MiglioranzaMH, Sant’anna RT, Becker LS, Magalhães E, et al. Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic. Arq Bras Cardiol. 2010;94(1):41-5. doi: http://dx.doi . org/10.1590/S0066-782X2010000100008. 16. Hibbard JH, Mahoney ER, Stock R, Tusler M. Do increases in patient activation result in improved self-management behaviors? Health Serv Res. 2007;42(4):1443-63. doi: 10.1111/j.1475-6773.2006.00669.x. 17. Hibbard JH, Greene J TM. Improving the outcomes of diseasemanagement by tailoring care to the patient’s level of activation. Am J Manag Care. 2009;15(6):353-60. PMID: 19514801. 18. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation where we are and where we should be going. Circulation. 2014;129(6):704-10. doi: 10.1161/ CIRCULATIONAHA.113.004498. 19. Esmerio FG, Souza EN, Leiria TL, Lunelli R, Moraes MA. Constant use of oral anticoagulants: implications in the control of their adequate levels. Arq Bras Cardiol. 2009;93(5):549-54. doi: http://dx.doi.org/10.1590/S0066- 782X2009001100017. 20. O’Connor A. User Manual – Decisional Conflict Scale (10 question format) [Internet]. Ottawa: Otawwa Hospital Research Institute; © 1993. p. 1–16. [Accessed in 2017 Feb 10]. Available from: http://decisionaid.ohri.ca/docs/ develop/User_Manuals/UM_Decisional_Conflict.pdf Archived at http:// www.webcitation.org/6nqIoQFCP 21. Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert ML, et al. Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Making. 1996;16(1):58-64. doi: 10.1177/0272989X9601600114. References Stephan LS, Almeida ED, Guimarães RB, Ley AG; Analysis and interpretation of the data and Statistical analysis: Stephan LS, Almeida ED, Guimarães RB, Ley AG, Leiria TLL; Obtaining financing: Stephan LS, Leiria TLL. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This article is part of the thesis of master submitted by Laura Siga Stephan, from Instituto de Cardiologia - Fundação Universitária de Cardiologia (IC/FUC). Ethics approval and consent to participate This study was approved by the Ethics Committee of the Instituto de Cardiologia / Fundação Universitária de Cardiologia under the protocol number 5043/14. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 13